Picture loading failed.

Anti-CFD therapeutic antibody (Pre-made Lampalizumab biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-293-1mg 1mg 3090
GMP-Bios-ab-293-10mg 10mg 21890
GMP-Bios-ab-293-100mg 100mg 148000
GMP-Bios-ab-293-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CFD therapeutic antibody (Pre-made Lampalizumab biosimilar,Fab)
INN Name Lampalizumab
TargetCFD
FormatFab
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI Structure4d9q:HL:ED/4d9r:HL:ED
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesTanox;Genentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDry age-related macular degeneration
Development Techna